Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE   immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Tarlatamab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE   immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC). ### Output: Tarlatamab